21 July 2021Aprea Therapeutics (APRE.Q) Announces Positive Results from Phase 2 Trial…Kieran Robertson APRE.Q Aprea Therapeutics (APRE.Q) today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML. “The…